Johnson & Johnson Announced Q1 2026 Earnings on April 14, 2026, Reporting "Worldwide sales were $24.1 billion for the quarter."

Johnson & Johnson reported first quarter 2026 financial results with worldwide sales of $24.1 billion for the quarter, an operational sales increase of 6.4 percent.

For the quarter, net earnings were $5.2 billion and diluted earnings per share were $2.14.

Adjusted net earnings for the quarter were $6.6 billion, and adjusted diluted earnings per share were $2.70.

Free cash flow in the first quarter was approximately $1.5 billion.

Executives highlighted that their "unique combination of innovative medicine and MedTech" is delivering resilient growth.

The innovative medicine division delivered operational sales growth of 7.4 percent in the quarter, while MedTech reported operational sales growth of 4.6 percent.

Management noted that their "priority is to invest behind our portfolio of new product launches and our promising pipeline programs" while they "remain opportunistic from a business development standpoint".The pipeline saw significant momentum with the recent FDA approval of ICOTYDE for the first-line treatment of plaque psoriasis, which management described as "the first and only IL-23 targeted oral peptide". In oncology, INLEXZO received a permanent J-code for reimbursement, and the FDA approved TECVAYLI plus DARZALEX FASPRO for relapsed or refractory multiple myeloma.

Within MedTech, TECNIS PureSee received FDA approval as an extended depth of focus intraocular lens, and the company made progress on their "OTTAVA robotic surgical system" with a second investigational device exemption trial underway.

For the full year 2026, the company is "increasing our operational sales guidance to be in the range of 5.9% to 6.9%, with a midpoint of $100.2 billion". The company estimates reported sales growth between 6.5 percent to 7.5 percent, with a midpoint of $100.8 billion for the full year.

Executives are "increasing our guidance by $0.02 to a range of $11.30 to $11.50" for adjusted operational earnings per share for the year.

Executives reaffirmed they have "a clear line of sight to double-digit growth by the end of the decade".